University of Michigan and Dr. Bill Chey are leading the way in nutritional care, research and education for irritable bowel syndrome (IBS). your support will help advance our understanding of how food IMPACTS the GI System in an effort to discover and improve treatments for patients. 

Current studies underway include:

  • Determining the role of the low FODMAP diet for pain and bloating in patients with IBS and constipation

  • Conducting studies to determine the most efficient and effective means of reintroducing FODMAPs in patients who improve after excluding FODMAPs from the diet

  • Identifying biomarkers which will help health care providers to determine which IBS patients are most likely to improve with the low FODMAP diet

  • Conducting a clinical trial to compare the effectiveness of psyllium, prunes, and kiwi as treatments for chronic constipation. 

  • Determining whether breath testing identifies IBS patients who are more likely to improve with the non-absorbed antibiotic rifaximin

  • Determine the best test to identify patients with intestinal enzyme deficiencies - an enzyme called sucrase isolmaltase is responsible for breaking down table sugar and starch

  • Testing a novel IgG antibody test which can identify patients with food sensitivities

  • Assisting in the development of a novel prebiotic which alters the gut microbiome in a way that improves the symptoms of lactose intolerance

  •  to learn more about Dr. Chey’s research and more, click here.

every dollar you donate to u. michigan WILL BE matchED up to $125,000! 


Cedars-Sinai and Dr. Mark Pimentel have provided landmark research for small intestinal bacterial overgrowth and irritable bowel syndrome. As research is often underfunded in this area, your donation can make a big impact. Mark Pimentel, MD, is currently the head of the Pimentel Laboratory and executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai. This program focuses on the development of drugs, diagnostic tests and devices related to conditions of the microbiome.

A FEW OF THE MOST SIGNIFICANT ACCOMPLISHMENTS OF THE PIMENTEL LABORATORY INCLUDE:

  • THE DISCOVERY OF RIFAXIMIN AS A TREATMENT FOR IRRITABLE BOWEL SYNDROME (IBS) WITH DIARRHEA

  • DEVELOPING THE FIRST BLOOD TEST FOR IBS ON THE BASIS OF IBS BEING DERIVED FROM ACUTE GASTROENTERITIS

  • DESCRIBING THE ASSOCIATION BETWEEN IBS AND SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO), WHICH FORMS THE BASIS FOR MICROBIOME THERAPIES IN THIS CONDITION

  • DETERMINING IBS/SIBO TO BE AN AUTOIMMUNE DISEASE

  • UNCOVERING THE METHANOGEN METHANOBREVIBACTER SMITHII (M. SMITHII) AS AN AGENT FOR CAUSING CONSTIPATION IN HUMANS

  • DISCOVERING THE USE OF LOVASTATIN AS A MICROBIOME TREATMENT FOR CONSTIPATION ON THE BASIS OF INHIBITING METHANE PRODUCTION BY METHANOGENS